InvestorsHub Logo
Followers 13
Posts 559
Boards Moderated 0
Alias Born 12/31/2012

Re: None

Thursday, 03/22/2018 6:17:38 PM

Thursday, March 22, 2018 6:17:38 PM

Post# of 3707
AMAG is responsible for Rekynda(bremelanotide) NDA submission with the FDA. Target is by end of 1st Qtr so could happen anyday now. AMAG licensed exclusive North American rights to develop and commercialize Rekynda, it's now their baby. All Spana has to do at this point is cash the checks... Recall that AMAG just got 2 FDA approvals at basically the same time so they have a good track record. IMO, Spana picked a solid company to partner with.

No more .01 warrants remain so this PTN bull run should continue with the upcoming catalysts IMHO.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent PTN News